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PREFACE
Allergic diseases are a global health problem that remainunder-diagnosed and often are not adequately treated.
Allergic rhinitis and urticaria, in particular, are examples of
bothersome conditions that can markedly impair the quality
of life of affected individuals through negative effects on
sleep, social activities (including sport and leisure), ability to
work, and school performance. These diseases cannot be
cured at the present time, but current first-line treatments such
as the highly effective nonsedating second-generation anti-
histamines can markedly reduce symptoms while at the same
time improving the patient’s well-being. They achieve these
benefits through simultaneous inhibition of two or more
chemical mediators involved in the immune-allergic cascade
and this suggests that they have advantages (rapid and pro-
longed action, once-daily administration, greater conve-
nience, and better tolerability/safety and efficacy) over first-
generation antihistamines.
In this satellite symposium the prestigious panel of
experts will provide their perspectives relating to advances
that are being made in our understanding of allergic/inflam-
matory disorders such as rhinitis and urticaria, and also some
recent clinical findings regarding the effectiveness of the
second-generation antihistamines in debilitating disorders
such as allergic rhinitis and chronic urticaria.
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SECTION 1. MULTIPLE PHARMACOLOGICAL
ACTIVITIES OF NOVEL ANTIHISTAMINES
Abstract
Allergic inflammation is a complex and multifactorial
IgE-mediated immuno-inflammatory cascade that is associ-
ated with the epithelial accumulation of effector cells such as
mast cells, eosinophils and basophils, and the formation and
release of a variety of different inflammatory mediators. The
chemical mediators that act in concert to produce these
effects can be divided into 3 groups: preformed granule
associated mediators (eg, histamine and proteases), phospho-
lipid-derived mediators [eg, eicosanoids and platelet-activat-
ing factor (PAF)], and chemokines and cytokines. The role of
histamine in allergic inflammation is unequivocal; however,
other mediators are clearly involved in the inflammatory
process and their roles are beginning to become better de-
fined. For example, PAF increases vascular permeability and
is becoming increasingly recognized as an important media-
tor. The clinical importance of PAF has been highlighted by
the finding that allergic responses, including anaphylaxis,
seem to be more severe in patients deficient in PAF-acetyl-
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hydrolase, the enzyme that inactivates PAF. There is an
emerging view that drugs that can inhibit a broader range of
inflammatory agents may prove to be more effective in
providing symptomatic relief in allergic disorders than those
targeted at a single mediator. In this regard, rupatadine is a
novel antihistamine that is also an inhibitor of PAF. Some
recent pharmacological and clinical findings with this agent
are presented in this overview.
INTRODUCTION
Allergic inflammation is a complex immune-inflammatorycascade that primarily developed as a protection against
parasite infestation. The chemical mediators which act in
concert to facilitate these effects can be divided into 3 types:
preformed granule-associated mediators (eg, mast cell-de-
rived histamine and proteases); newly generated phospholip-
id-derived mediators [eg, eicosanoids and platelet-activating
factor (PAF)], and macromolecular chemokines and cyto-
kines (Fig. 1-1). The role of histamine as a prominent medi-
ator in the pathophysiology of allergic rhinitis and urticaria is
unequivocal. Antihistamines have traditionally been consid-
ered to exert their effects through antagonism of H1-recep-
tors. However, today, we have a better understanding of the
mechanism of action of this class of drugs and they seem to
act on the H1-receptor in a positive (agonist) way and they are
now classed as inverse agonists.1–3 Histamine is clearly not
the only mediator involved in the inflammatory process and
there is an emerging view that drugs which can inhibit a
broader range of inflammatory agents may prove to be more
effective in providing symptomatic relief in both allergic
rhinitis and chronic urticaria.4
ALLERGIC RHINITIS AND URTICARIA
Allergic rhinitis and urticaria are diseases or, more
appropriately, groups of diseases that between them represent
one of the most common reasons for a patient to visit their
general practitioner. They are clearly very different diseases,
but given the fact that they are both responsive to treatment
with antihistamines, do they have elements in common?
As its name indicates allergic rhinitis is an immunologic
disease resulting from allergen provocation (pollen, molds,
mites, etc) within the nasal passages and after initial sensitiza-
tion, there is a well-defined cascade of events that follows:
Y IgE-mediated stimulation of resident effector cells, such
as mast cells
Y Early phase inflammatory response that is mainly mast
cell-mediated (sneezing, itching, and rhinorrhoea)
Y Immune system activation (T- and B-lymphocytes)
Y Influx and activation of secondary effector cells such as
neutrophils, basophils, eosinophils, etc.
Y Development of allergic inflammation, involving acti-
vated effector cells, particular the eosinophils, leading to
nasal congestion/blockage.
Given the diversity of the allergic cascade and the
immune response that it elicits, it is not surprising that it can
vary between individuals. Indeed, genetic polymorphisms
exist that can influence the IgE-mediated response and the
“make-up” of cytokines that are produced after provocation.5
Our group undertook a study that investigated the dermal
cytokine response to allergen in 11 patients and we observed
11 different cytokine responses.6 This suggests that genetic
factors are important and that an individual’s response to an
allergen can be influenced at a number of levels: different
mast cell response, different immune cell activation, different
effector cell responses, and different sensitivity to the re-
leased inflammatory mediators.
Allergen provocation and its subsequent IgE-mediated
immune response have a far less important role in the patho-
genesis of urticaria. Other factors such as Complement frac-
tions, IgG complexes associated with autoimmune diseases,
neuropeptides, and many others may be involved. Stress can
also be important and clearly exacerbates urticarial disease.7
As with allergic rhinitis, histamine is a key mediator in the
symptomatology of urticaria and this comes from 2 pieces of
evidence:
Y H1-receptors are present on the blood vessels in the skin,
and they are responsible for local vasodilatation and,
ultimately, local edema (wheal)
Y H1-receptors are present on the sensory nerves in the
skin, and these are responsible for the local flare re-
sponse and subsequent itching (pruritus)
However, as with allergic rhinitis, the individual re-
sponses to histamine release and the reaction to it are vari-
able. Furthermore, a wide range of eliciting stimuli have been
implicated in the pathogenesis of urticaria including physical
factors, drugs, foodstuffs, infectious agents, autoimmunity,
cold, etc. This diversity, combined with the individual re-
sponse to provocation and stress, makes urticaria a family of
diseases in which every patient can be considered different.
PLATELET ACTIVATING FACTOR (PAF)
PAF was discovered and named in the early 1970s by
Benveniste and colleagues who were investigating leukocyte-
dependent mechanisms of histamine release from rabbit
platelets.8 They found that basophils sensitized with IgE
degranulated in the presence of allergen, releasing histamine
and a factor (PAF) that caused aggregation of platelets and
FIGURE 1-1. Mediator release associated with mast cell
degranulation after allergen exposure.
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release of histamine. They also proposed a role for PAF as a
highly potent mediator in the immediate hypersensitivity-type
allergic reaction and anaphylaxis.
As noted earlier, there are 3 main groups of mediators
associated with mast cell degranulation. PAF is one of the
group of secondary mediators and is a by-product of arachi-
donic acid synthesis, which is also responsible for the pro-
duction of prostaglandins and leukotrienes. PAF can be
produced by different pathways; there is the classic method
involving mast cells, but an alternative route involving mac-
rophage activation has been identified in mice.9
The receptor for PAF is a G-protein coupled receptor
which is significantly up-regulated in allergic diseases. For
example, in the nose it is present in a wide range of different cell
types, but particularly in inflammatory cells (Fig. 1-2).10 With
respect to allergic rhinitis, PAF increases vascular permeability
and this contributes to the increased mucous secretion and
rhinorrhoea associated with the disease. PAF also attracts and
activates granulocytes within the nasal endothelium and this
exacerbates the inflammatory response in nasal tissues. In this
regard, our group found that in tissue samples granulocyte
accumulation occurred very rapidly (within 8 minutes of P-
selectin translocation) and this reaction is more consistent with
PAF-release than with the usual cytokine response (that is slow
and takes 12 hours to peak).11,12
PAF-acetylhydrolase, the enzyme that metabolizes
PAF to inactive lyso-PAF (Fig. 1-3) has a number of poly-
morphisms and this has been shown to have a number of
clinical implications. For example, Li and colleagues recently
reported that in patients homozygous for the Arg 92 allele,
PAF-acetylhydrolase activity was higher than in patients with
the HIS 92 allele.13 Furthermore, PAF-acetylhydrolase activ-
ity was higher among survivors at 7 days compared with
nonsurvivors at 7 days (Fig. 1-3). The authors noted that these
data demonstrate an association between PAF-acetylhydro-
lase allelic variation, plasma PAF activity and clinical out-
come in acute respiratory distress syndrome.13
A similar relationship has been reported for PAF, PAF-
acetylhydrolase and severe anaphylaxis.14 PAF-acetylhydrolase
levels were measured in 9 patients with peanut allergy who had
fatal anaphylaxis and these were compared with values from a
range of control subjects (adults, children, allergic, nonallergic,
and survivors of anaphylaxis). The proportion of patients with
elevated PAF levels increased from 4% in the control group to
20% in a group with grade 1 anaphylaxis, 71% in a group with
grade 2 anaphylaxis, and 100% in those with grade 3 anaphy-
laxis (P  0.001). The authors noted that serum PAF-acetylhy-
drolase activity was significantly lower in patients with fatal
peanut anaphylaxis compared with controls (P  0.001 for all
comparisons) and concluded that increased PAF activity may
contribute to the severity of anaphylaxis.14
RUPATADINE
Rupatadine is a potent second-generation antihista-
mine that has been shown to possess a number of anti-
inflammatory properties (Fig. 1-4).15 Of interest in relation
to this presentation, rupatadine is a powerful antihistamine
that, in addition, has been shown to be a potent inhibitor of
PAF-receptors.
Pharmacokinetic studies have shown that it is rapidly
absorbed with a tmax of 45–60 minutes,16 and this has been
confirmed in clinical studies.15
A plot of rupatadine plasma concentration versus flare
inhibition highlights a hysteresis loop-like response, with the
highest plasma concentration observed after 5 hours, but
sustained inhibition of the flare reaction being prolonged and
still clinically significant after 72 hours (Fig. 1-5). This
indicates that rupatadine penetrates and resides within the
tissues, and explains its long duration of action, facilitating
once-daily administration.
Clinical trials in patients with seasonal allergic rhinitis,
perennial rhinitis, persistent rhinitis, and chronic urticaria have
shown that rupatadine is at least as effective as drugs such as
FIGURE 1-2. Platelet activating factor (PAF) and nasal
inflammation.
FIGURE 1-3. Platelet Activating Factor (PAF) metabolism
and acute respiratory distress syndrome.13
FIGURE 1-4. Structural formula and some key properties
of rupatadine.15,16
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loratadine, cetirizine, desloratadine, and ebastine. In these trials
it was very well tolerated and, importantly, it demonstrated no
untoward cardiovascular, cognitive, or psychomotor effects.15
CONCLUSIONS
Y Allergic inflammation is a complex immune-inflamma-
tory cascade involving a wide array of mediators and
effector cells
Y The role of histamine in the allergic/inflammatory re-
sponse is unequivocal, but other mediators such as PAF
are also involved
Y PAF is a potent mediator of vascular permeability
thereby exacerbating rhinorrhoea
Y PAF is a potent attractor and activator of granulocytes and
monocytes thereby exacerbating allergic inflammation
Y PAF increases the synthesis of histamine thereby exac-
erbating all histamine mediated effects
Y PAF increases ‘sensitizes’ tissues to, for example, his-
tamine and bradykinin thereby exacerbating allergic
symptoms
Y Failure to metabolize PAF exacerbates acute respiratory
distress syndrome and anaphylaxis
Y There is an emerging view that drugs that can inhibit a
broader range of allergic/inflammatory mediators may
prove to be more effective in both allergic rhinitis and
chronic urticaria
Y Rupatadine is a powerful antihistamine that, in addition,
has been shown to be a potent inhibitor of PAF-receptors
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The Allergic Rhinitis and its Impact on Asthma (ARIA)
workshop group, in collaboration with the World Health Orga-
nization, introduced a new classification system for allergic
rhinitis based on the duration of symptoms and their severity.
Persistent allergic rhinitis (PER) is defined as rhinitis in which
the symptoms occur more than 4 days per week and for more
than 4 weeks. The disease is further classified into mild or
moderate-severe depending on the level of impairment (sleep
disturbances, impairment of activities, etc). Interestingly, the
prevalence of PER demonstrates a wide geographic distribution
and it is the most common form of rhinitis in Latin America,
accounting for about 70% of cases. Rupatadine is a novel
nonsedating second-generation antihistamine, which is also a
PAF antagonist, which we evaluated in the treatment of PER in
500 Latin American patients. In this randomized, double-
blind, placebo-controlled trial rupatadine 10 mg once-daily was
compared with cetirizine 10 mg once daily over a 12-week
period. Both rupatadine and cetirizine significantly improved
6-symptom Total Symptom Scores at 4 and 8 weeks, but only
rupatadine produced a statistically significant improvement at 12
weeks (P  0.008). Importantly, both rupatadine and cetirizine
significantly improved overall scores for quality of life, but only
rupatadine significantly improved ocular symptoms (P  0.01).
In this trial, and in a 12-month safety study, rupatadine was
found to be well-tolerated, produced no evidence of car-
diotoxic effects and was associated with a high rate of
FIGURE 1-5. Hysteresis of plasma rupatadine concentra-
tion and inhibition of histamine mediated flare response.
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treatment compliance. These data indicate that once daily
rupatadine is a good treatment option for patients with
PER and it well-received by patients, as evidenced by high
rates of long-term compliance.
INTRODUCTION
The Allergic Rhinitis and its Impact on Asthma (ARIA)workshop group, in collaboration with the World Health
Organization, have introduced a new classification system for
allergic rhinitis based on the duration of symptoms and their
severity.1,2 Persistent allergic rhinitis (PER) is defined as a
symptomatology that occurs on more than 4 days per week,
and for more than 4 weeks (Fig. 2-1). This is further classified
into mild or moderate-severe disease depending on sleep
disturbances, impairment of daily activities (including sport
and leisure), abnormal work or school, or how troublesome
the symptoms are.
With regards to allergic sensitization, while pollens are
the most frequent allergens associated with intermittent rhi-
nitis, in persistent disease pollens and mites are equally
common.3 In terms of prevalence rates for PER, there is a
marked geographical variation. For example, Bachert and
colleagues (2006) reported that in Europe 40% of cases of
allergic rhinitis comprised PER (35% had moderate-severe
disease) and 60% intermittent disease (40% moderate-se-
vere).4 However, in Latin America moderate-severe PER
accounts for almost 70% of cases of allergic rhinitis.5 This
may be explained by the much greater proportion of the year
when mite allergen is present, especially in northern regions
of the continent (including Central America) with its subtrop-
ical climate.
PER is a disease which places a significant burden on
patients in terms of nasal allergy symptoms because they
affect many aspects of daily life (Fig. 2-2).6 Effective treat-
ment to alleviate the symptoms of the disease is important for
improving daily functioning and quality of life (QoL). The
ARIA guidelines recommend intranasal corticosteroids as
first-line therapy in patients with moderate-severe PER.1
However, second-generation nonsedating antihistamines re-
main an important therapeutic option (Fig. 2-3). As noted in
the ARIA guidelines pharmacological therapy for PER needs
to take into account a number of factors including: efficacy,
safety, cost-effectiveness, patient preference, objectives of
treatment, likely adherence to treatment recommendations,
severity and control of the disease, and the presence of
comorbidities. Patient preference is an important and often
underrated consideration, since usage statistics show that
nonsedating antihistamines are more widely used than intra-
nasal corticosteroids in many counties worldwide, which is
contrary to ARIA guideline recommendations. An almost iden-
tical situation has been reported in Latin America with two-
thirds of physicians prescribing antihistamines for their PER
patients despite the majority of them having moderate-severe
disease.7 Interestingly, most physicians (82%) prescribed anti-
histamines short-term (30 days or less) whereas 52% of physi-
cians prescribed intranasal steroids for less than 30 days.
RUPATADINE: BACKGROUND
A wide range of nonsedating second-generation of
antihistamines are currently available including drugs such
as cetirizine, desloratidine, ebastine, fexofenadine, levoce-
tirizine, loratadine, mizolastine, and rupatadine. The one
property that they have in common is that they all act at the
H1-receptor, and it is therefore likely to be ancillary
properties that differentiate the various products and de-
FIGURE 2-1. ARIA classification for allergic rhinitis.1,2
FIGURE 2-2. Impact of nasal allergy symptoms in patients with allergic rhinitis.6
WAO Journal • April 2010, Supplement Symposium Report
© 2010 World Allergy Organization S5
fines their optimal utility. For example, histamine is
clearly not the only mediator involved in the inflammatory
process and there is an emerging view that drugs which can
inhibit a broader range of inflammatory agents may prove
to be more effective in providing symptomatic relief in
allergic disorders.8 Interestingly, some antihistamines have
displayed marginal platelet activating factor (PAF)-antag-
onistic properties; activity that cannot be attributed to
specific interaction with PAF receptors. In contrast, rupata-
dine appears to be novel in this regard since it specifically
inhibits PAF receptor.9–11 Furthermore, rupatadine has dem-
onstrated anti-inflammatory effects through inhibition of mast
cell degranulation (mediated by various immunologic and
nonimmunologic stimuli), and inhibition of eosinophil and
neutrophil chemotaxis, cytokine (IL-5, IL-6, IL-8, GM-CSF,
and TNF-) production, and neutrophil adhesion molecule
(CD 11b and CD 18) expression (Fig. 2-4).11
RUPATADINE: CLINICAL EVIDENCE
The efficacy and safety of once-daily rupatadine in the
management of allergic rhinitis in adolescents and adults
(aged 12–65 years) has been investigated in a broad range of
controlled trials (Box 2-1). Results from the dose-ranging
trials found the 10 mg once-daily dosage to be optimal in
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FIGURE 2-3. ARIA treatment guidelines for allergic rhinitis.1,2
FIGURE 2-4. Effects of rupatadine in allergic inflammation.
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Rupatadine in Persistent Allergic Rhinitis (PER)
In Latin America, a large Phase IV randomized, dou-
ble-blind, placebo-controlled, 12-week clinical trial was un-
dertaken to compare the efficacy and tolerability of rupata-
dine 10 mg once daily with cetirizine 10 mg once daily in
more than 500 patients with confirmed PER according to
ARIA criteria.12 The main results from the trial, in terms of
changes from baseline in total symptom score (TSS) for 6
symptoms after 12 weeks, are shown in Table 2-1, while the
changes at 4, 8, and 12 weeks are highlighted in Figures 2-5.
The improvement in TSS was not statistically signifi-
cant in the placebo group at any time during the study. In
contrast, both rupatadine and cetirizine significantly reduced
TSS at 4 and 8 weeks compared with baseline values, but
only rupatadine produced a statistically significant improve-
ment at 12 weeks (P  0.008).
QoL was also measured in this trial using the Rhinocon-
junctivitis Quality of Life Questionnaire (RQLQ) and both
rupatadine and cetirizine significantly improved overall scores
and scores for the activities, sleep, and nasal symptom domains
(P  0.01). However, only rupatadine statistically significantly
improved ocular symptoms (P  0.01; Fig. 2-6).
Other clinical trials in patients with PER include the
XPERT trial13 involving levocetirizine and the ACCEPT2 trial14
that investigated desloratadine. In both these trials, the antihis-
tamines reduced 5-symptom TSS by 40% and this compares
with the 50% reduction in 6-symptom TSS observed in our Latin
American study. Interestingly, it has been shown that long-term
antihistamine treatment results in greater reductions in symp-
toms of PER with time and this was associated with a statisti-
cally significant improvement in QoL.13
Recently, a 1-year study involving rupatadine 10 mg once
daily in patients with PER has been published.15 This was an
open-label Phase IV safety trial involving 324 patients followed
for 6 months and 120 patients who continued treatment for 12
months. Compliance with treatment was very high in this trial;
89.6% at 6 months and 83.3% at 12 months. These data indicate
a high level of satisfaction, and presumably perceived benefit, by
patients taking rupatadine. Overall, the tolerability of rupatadine
was very good and the most frequent adverse effects were dry
mouth, headache, and somnolence and, interestingly, all 3 ad-
verse effects were decreased at 1-year compared with the inci-
dence at 6 months: 0.83 versus 2.2%, 0.83 versus 6.5%, and 5.8
versus 7.7%, respectively. Another important finding in this trial
was the lack of abnormal ECG findings over the 12-month study
TABLE 2-1. Change From Baseline in Total Symptom









(n  174) Test*
Baseline
Instantaneous 8.96 (3.25) 8.72 (2.90) 8.21 (3.07)
Reflective 10.15 (2.41) 9.90 (2.07) 9.69 (2.16)
Final
Instantaneous 5.48 (3.65) 4.55 (2.90) 4.53 (3.40)
Reflective 5.62 (3.62) 4.79 (2.85) 4.79 (3.46)
Change from
baseline
Instantaneous 3.48 (3.62) 4.17 (3.23) 3.67 (3.86) P  0.025
Reflective 4.53 (3.44) 5.11 (2.92) 4.90 (3.50) P  0.067
% Change from
baseline
Instantaneous 38.8% 47.8% 44.7%
Reflective 44.6% 51.6% 50.6%
• Doses evaluated:
• 2.5, 5, 10, or 20 mg rupatadine, once daily
• Treatment duration:
• 14 days (Seasonal Allergic Rhinitis)
• 28 days (Perennial allergic Rhinitis)
• Design:
• International, multicentre, randomized,
double-blind
• In parallel groups
• Control group/active treatments:
• Placebo
• Ebastine (10 mg)
• Loratadine (10 mg)
• Cetirizine (10 mg)
BOX 2-1. Clinical trials in allergic rhinitis
FIGURE 2-5. Change from baseline in instantaneous Total Symptom Score (TSS) at 4, 8, and 12 weeks in patients with per-
sistent allergic rhinitis treated with placebo, cetirizine, or rupatadine.12
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period, suggesting a lack of cardiotoxicity.15 QoL was also
investigated using the RQLQ questionnaire and rupatadine pro-
duced statistically significant improvements in the domains
assessing sleep, emotions, and ocular symptoms within 1 month
of initiating treatment.16 Furthermore, over the 6- and 12-month
treatment periods QoL scores continued to improve significantly
from baseline values in the rupatadine group (P  0.0001).
These findings, combined with those from other clinical trials
assessing QoL in patients with allergic rhinitis, have clearly
demonstrated the positive benefit that rupatadine has on patient
well-being.
Rupatadine; Fast Onset of Action
From the patient’s perspective, rapid relief of nasal
symptoms and the return to their usual lifestyle would be
an important attribute for any drug used to treat allergic
rhinitis. In this regard, rupatadine has been reported to
have a fast onset of action in patients with seasonal
rhinitis, perennial rhinitis, PER, and chronic urticaria.11 In
an experimental model using the Vienna Challenge Cham-
ber, rupatadine 10 mg once daily significantly reduced
total nasal symptom scores compared with placebo within
15 minutes of allergen exposure. This rapid response
compared favorably with results achieved with other anti-
histamines such as loratadine and levocetirizine that had
previously been tested in this model.17
CONCLUSIONS
Y In Latin America PER is the most common presentation
of allergic rhinitis, representing almost 70% of cases
Y Second-generation antihistamines are a first-line treat-
ment option in patients with moderate-severe disease
and seem to be favored over intranasal corticosteroids,
despite the latter being the recommended treatment
choice in the ARIA guidelines
Y Patient preference may play an important role in this
treatment choice
Y Generally speaking, the antihistamines are used short-
term (30 days) despite evidence of increased benefits
with longer-term treatment
Y Rupatadine is a second-generation antihistamine that is
also a potent antagonist of PAF-receptors, and it also
inhibits other inflammatory mediators/effector cells
Y In clinical trials rupatadine was found to be an effec-
tive and safe/well-tolerated treatment option in pa-
tients with PER; it reduced nasal and ocular symp-
toms and also improved a number of aspects of the
patient’s QoL
Y With once-daily administration rupatadine had a fast
onset of action and an extended duration of activity
providing 24-hour cover
Y Clinical trials up to 1-year in duration confirmed the
safety of rupatadine 10 mg once daily and found no
evidence of any cardiotoxic effects
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SECTION 3. EFFECTIVE NEW ANTIHISTAMINES
IN DERMATOLOGY: URTICARIA AND OTHER
CONDITIONS
Abstract
Modern nonsedating antihistamines that target the
H1-receptor are the drugs of choice in the treatment of
histamine-mediated inflammatory skin disorders such as
urticaria. The modern agents, including rupatadine, the
latest addition to our repertoire, lack the unwanted effects
of older generation antihistamines (sedation and anticho-
linergic effects) and exhibit additional anti-inflammatory
effects. Rupatadine, for example, has been shown to inhibit
platelet-activating factor (PAF) and mast cell activation. In
well-controlled clinical trials rupatadine has been shown to
be safe and effective in treating patients with chronic
spontaneous urticaria. For example at a dosage of 20 mg once
daily it produced a50% reduction of urticarial activity in 3 of
4 patients treated and more than half the patients achieved a
reduction in symptoms exceeding 75%. Importantly, the clinical
benefits obtained in these patients were mirrored by improve-
ments in their quality of life. In addition, treatment with rupata-
dine 20 mg once daily was shown to be effective in treating
patients suffering from cold urticaria. Thus, rupatadine, a sec-
ond-generation antihistamine that is also a potent PAF-antago-
nist, is a novel and promising new treatment option for patients
with urticaria.
INTRODUCTION
Historically, as a class, the H1-antihistamines (AHs) havebeen commonly used to treat dermatological complaints
in which itch is a symptom. This includes disorders such as
atopic dermatitis, allergic contact dermatitis, mastocytosis,
psoriasis, pruritus, bullous pemphigoid, and urticaria. As a
consequence of this, combined with their widespread use in
rhinosinusitis, the AHs represent one of the most frequently
administered classes of medicine. This has led to concerted
effort, which started in the 1930s, to develop more effective
and safer/better tolerated products (Fig. 3-1).
The first-generation AHs, however, were beset with
significant adverse effects, most notably sedation and im-
paired psychomotor performance. Since the 1970s, the
focus has been directed toward maintaining the potent
anti-H1 activity, while improving on the safety profile.
This was achieved with the introduction of second-gener-
ation AHs and a more recent aim has been to produce
agents with no cardiotoxic effects, because 2 of the newer
compounds (terfenadine and astemizole) were associated
with QTc prolongation and occasional episodes of life-
threatening torsades de pointes.1 Interestingly, while
safety issues clearly need to be a priority, recent develop-
ments have focused on producing AHs that have anti-
inflammatory effects that are additive to their activity at
the H1 receptor. This is based upon the fact that histamine
is clearly not the only mediator involved in the inflamma-
tory process, and the current view is that drugs which can
inhibit a broader range of inflammatory agents may prove
to be more effective in providing symptomatic relief in
urticaria.2 In this regard rupatadine is an interesting
“newer” nonsedating second-generation AH because it has
also been shown to be an powerful inhibitor of PAF
receptors (for a review see Mullol et al 2008).3
In this review the aim is to discuss the benefits of AH
therapy with a focus on rupatadine in the management of
urticaria; a common and debilitating disorder in which mast
cells play a key pathogenic role.
URTICARIA
Urticaria is a common debilitating skin disorder that is
characterized by wheals, flare/erythema and pruritus, and is
often accompanied by angio-edema. Historically, the etiology
of the disorder has been poorly defined and this has led to it
being referred to as chronic idiopathic urticaria in many
instances. However, in recent times many of the underlying
causes of urticaria have been better defined and a classifica-
tion system based upon etiology and other clinical features
has been developed (Box 3-1).4
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FIGURE 3-1. Development of antihistamines.
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Our current understanding regarding the pathogenesis
of urticaria is outlined in Figures 3-2. As can be seen the
chain of events leading to the development of urticaria
symptoms is initiated by one of the many pathways that result
in mast cell activation (Box 1). Activated mast cells respond
by releasing a range of mediators of which histamine is the
most important, but others such as PAF, various interleukins,
GM-CSF, TNF, etc, also contribute to the inflammatory re-
sponse. Urticarial symptoms are mediated via activation of
nerves, vasodilatation of blood vessels in the skin, extravasation
of fluid to form a wheal, and recruitment of inflammatory cells.
RUPATADINE IN CHRONIC SPONTANEOUS
URTICARIA
The efficacy of rupatadine has been evaluated in a
number of trials involving patients with chronic spontaneous
urticaria. In a dose-finding study Dubertret and coworkers
(2007) found that rupatadine 10 and 20 mg for 4 weeks
significantly reduced mean pruritus severity scores from
baseline values by 62% (P  0.05) and 72% (P  0.001),
respectively, and mean number of wheals by 45 and 58%,
respectively.5 The investigators’ global assessment of symptom
severity after 4 weeks was rated as “good improvement” for the
majority of patients treated with rupatadine 10/20 mg (Fig. 3-3).
Similar improvements in mean pruritus severity scores and
mean number of wheals after 4 weeks’ treatment with rupata-
dine 10 and 20 mg was reported by Gimenez-Arnau and col-
leagues (2007) in patients with chronic spontaneous urticaria.6
Importantly, the clinical benefits obtained in this random-
ized, double-blind, placebo-controlled trials were mirrored by
improvements in the quality of life (QoL) of patients (Fig. 3-4).
A pooled analysis of the above 2 studies not only
confirmed the efficacy of rupatadine in the treatment of
chronic urticaria; a responder analysis highlighted the
benefits of using the higher dosage of rupatadine 20 mg
once daily (Fig. 3-5).7 The authors note that these results
support the use of higher than standard dosages of nonse-
dating antihistamines such as rupatadine for patients with
urticaria.
Overall, the results of studies to date confirm that
rupatadine 10 and 20 mg are effective and safe in the
treatment of chronic spontaneous urticaria. Rupatadine 20
mg was significantly more effective and equally safe
compared with rupatadine 10 mg. If symptoms persist, we
have used rupatadine 40 mg in our clinic with additional
clinical benefit.
RUPATADINE IN COLD URTICARIA
The urticarial response of cold urticaria patients to
temperature is extremely variable as can be seen in Figures
3-6. Some individuals react when the temperature is low,
whereas others develop wheals at temperatures relatively
close to normal skin temperature.8
Together with Dr. Gimenez-Arnau and her team at the
Hospital del Mar Barcelona, our group undertook a placebo-
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FIGURE 3-2. Pathogenesis of urticaria.
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controlled clinical trial to investigate the effects of rupatadine
20 mg on the cold urticaria response in 21 adult cold urticaria
patients.9 We used TEMP test 3.0, a cold-provocation device
that can apply 12 different temperatures to the skin of the
patient to determine the critical temperature threshold at
which urticaria symptoms occur. In this study rupatadine 20
mg significantly lowered the threshold temperature (P 
0.0006) whereas placebo had no effect. Symptoms associated
FIGURE 3-4. Improvement in life quality (%) after 4 weeks’ treatment with rupatadine 10 and 20 mg and placebo in pa-































FIGURE 3-5. Responder rates in a pooled analysis of 2 clinical trials involving patients with chronic spontaneous urticaria
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FIGURE 3-3. Investigators’ global assessment of symptom severity after 4 weeks treatment with rupatadine 5, 10, and 20
mg in patients with chronic spontaneous urticaria.5
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with cold urticaria such as pruritus and burning were also
significantly reduced after administration of rupatadine 20
mg, to the point where 80% of patients had no or mild
reactions after treatment.
ADDITIONAL EFFECTS OF BLOCKING
HISTAMINE AND PAF
Injections of histamine and PAF into the skin both
result in a local inflammatory response with a wheal and flare
reaction which is associated with itch.10,11 These symptoms
are identical to those observed after a mosquito bite and have
given rise to the view that treatment with rupatadine, which
possesses both antihistamine and anti-PAF activity, may help
alleviate the reaction to insect bites. This theory was explored
in a recent double-blind, placebo-controlled, crossover study
in which 30 mosquito bite sensitive adults received either
rupatadine 10 mg or placebo once daily for 4 days.11 On day
3 during the 2 treatment periods, the participants received 2
bites from an Aedes aegypti mosquito on their forearm.
Rupatadine significantly reduced wheal size at 15 minutes by
48% compared with placebo (P  0.0003) and pruritus by
21% (P  0.019). For people who react badly to mosquito
bites, prophylactic rupatadine once daily may prove to be
useful for limiting the wheal/flare/itch response when they
visit mosquito endemic areas.
CONCLUSIONS
Y PAF and histamine are important proinflammatory cu-
taneous mediators
Y Urticaria, which is provoked by activated mast cells and
their release of proinflammatory mediators such as his-
tamine and PAF, comes in many different forms
Y Modern nonsedating antihistamines such as rupatadine
are effective in the treatment of chronic spontaneous
urticaria
Y Rupatadine has also been shown to be effective in other
conditions such as cold-induced urticaria and as a pro-
tectant against symptoms after mosquito bites.
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SECTION 4. MANAGEMENT OF ALLERGIES IN
THE PRIMARY CARE ENVIRONMENT
Abstract
It is well recognized that globally, allergies of one kind
or another, are on the increase. Most countries in the world
have a very small number of trained allergists to meet the
growing demand for care. In the UK, for example, it has been
calculated that there is one specialist allergist per 1.1 million
people. Invariably most sufferers visit their general practitio-
ner (GP) in the first instance to determine what the problem
is. There is frequently a mismatch in understanding between
the GP and patient as to what the diagnosis and solutions are,
and this has led some patients to seek alternative practitioners
to help fill the “NHS void.” Highlighting the nature of the
problem are the results from a cross-sectional population-
based survey in Europe that demonstrated that although
allergic rhinitis had a relatively high prevalence (23%) it
frequently went unrecognized (by patients), undiagnosed and
untreated or not treated at all. This finding is compounded by
results from a GP audit, which reported that a relatively low
number of participants with a declared interest in allergic
rhinitis and respiratory disorders met the recommendations
contained within the Consensus Statement for the manage-
ment of allergic rhinitis. Possible solutions include the cre-
ation of GPs with a special interest (GPSI) in allergy posi-
tions in the community, inclusion of structured teaching at the
under- and postgraduate level, provision of “how to” litera-
ture and greater co-operation between specialists and GPs.
Only if we address the situation in a systematic manner will
we make an impact on patient care and clinical outcomes.
THE ALLERGY PROBLEM
Globally there is a significant increase in the prevalence ofallergy, including more serious diseases associated with
hospitalization (Fig. 4-1).1 In the UK there is a growing
professional consensus that both generalist and specialist
services are failing to keep up with the increased demand and
thus failing to provide acceptable levels of care for many
patients with allergy.2
A number of theories are proposed to explain this
underperformance:
Y The relatively high prevalence of allergy. In the UK for
example, it has been estimated that 32% of the popu-
lation have suffered from an allergy at some stage
(representative values for some other countries are:
Japan 40%, Germany and Sweden 30%, US and France
20%, and Italy and S. Africa 10%).3
Y In the UK there are about 320 million patient/physician
consultations per year and about 20 million of these are
related to allergic disorders.4,5
Y And perhaps most enlightening of all is the small num-
ber of specialist allergists available to advise and treat
allergy patients (for the countries listed above the num-
ber are: UK 1:1,083,303; Japan 1:61.200; Germany
1:16,000; Sweden 1:42,857; US 1:65.546; France
1:1,240,000; Italy 1:43,200; S. Africa 1:1,666,666).3
The above numbers highlight the divide between high rates
of disease prevalence and low rates of specialist medical
care and help to explain the under-recognition, underdiag-
nosis and undertreatment of allergic rhinitis. In the UK, for
example, there are clearly too few allergy specialists for
the size of the patient population and certain parts of the
country have no cover at all. This gives rise to other issues,
and one in particular is the “growth industry” involving provid-
ers of so-called alternative treatments and diagnostics (nearly all
of them completely unproven) that has developed to fill the
“NHS void.”
Another potential problem, given the lack of medical
resources and time that can be committed to individual
patients, is inappropriate and inadequate diagnosis and/or
management. Physicians need to understand their patients
and listen for warning signals, since we live in an age when
allergies are blamed for many complaints, often inappropri-
ately. For example, a patient consulting their physician stat-
ing that they believe that they are allergic to peanuts probably
is allergic to peanuts. On the other hand a patient who comes
to the clinic with a nonspecific complaint such as . . . .“I have
something wrong with me, perhaps it is an allergy-
” . . . . needs more careful consideration. The term allergy is
improperly used by patients and health care professionals
alike. When a patient states that they are worried they may
have an allergy, it is likely that they are trying to say: I have
something wrong with me. I cannot figure out what it is;
maybe it’s an allergy?
The temptation is to resort to diagnostic tests (IgE/skin
prick tests) when the more appropriate response is to try and
understand the nature of the underlying problem. It may of
FIGURE 4-1. The changing rate of hospitalizations from
certain allergic disorders 1990–2000.1
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course be an allergy, but it may not. The starting point is to
establish what it is that is really concerning the patient.
Misinterpretation of diagnostic tests is another potential problem
area particularly those results that are obtained from hair or nail
samples that have no validity. Results of tests can only be
interpreted in the light of the individuals history and symptoms
that requires diagnostic skill and judgment. Finally, and perhaps
most importantly, we need to consider the patient’s expectations
from the consultation, which generally are:
Y To be taken seriously by their healthcare professional
Y To have reasonable investigation of their problem and
investigation of possible triggers if it is an allergy
Y Advice regarding how to avoid the problem in future
Y Appropriate treatment/management
Y And to feel that they are being managed appropriately
within and integrated healthcare system.
ALLERGIC DISEASES: CURRENT MANAGEMENT
SITUATION
In practice how well are we doing with regards diag-
nosis of allergic rhinitis? Durham and coworkers (2002)
undertook an interesting cross-sectional, population-based,
epidemiological survey using computer-assisted telephone
interviews to ascertain the prevalence and diagnosis of aller-
gic rhinitis in almost 10,000 adults in 6 European countries.6
The main findings of this survey are highlighted in Fig. 4-2
and they demonstrate that allergic rhinitis has a high preva-
lence in Europe (23%), it is frequently undiagnosed and often
goes untreated. In terms of primary care, our group undertook
a survey involving approximately 200 general practitioners
(GPs) in the UK with a self-declared interest in allergic
rhinitis and respiratory disorders, and we compared their
management approach with the recommendations contained
within the Consensus Statement on the treatment of allergic
rhinitis.7 The main results from this survey are highlighted in
Table 4-1 and demonstrate that relatively few GPs achieved
the criteria set out in the Consensus Statement.7 It is impor-
tant to note, however, that the recommendations were de-
signed for secondary care physicians and, so, the findings
need to be interpreted in the context of applying specialist
standards in a primary care setting. At the time of the survey
there were no published guidelines for the management of
allergic rhinitis in primary care. This has now been rectified
after the publication of guidelines by the International Pri-
mary Care Respiratory Group (IPCRG).8
The above findings highlight the scope for improve-
ment that can be made in the primary care management of
allergic disorders. This is reinforced from results relating to the
number of GPs who correctly met the criteria for making an
accurate diagnosis and management based upon symptom as-
sessment, elimination of other causes, diagnostic tests, treatment
options, etc (Fig. 4-3).7 The data are useful because they can
assist us in designing future educational programs targeted at
areas requiring the greatest improvement.
When the costs of treatment for allergic rhinitis are
taken into consideration the above findings become even
TABLE 4-1. The Number and Percent of GPs Meeting
Consensus Statement Standards for Allergic Rhinitis in a UK




Standard 1: Identification of symptoms 26 13.8
Standard 2: Collection of information to
support a clinical diagnosis
43 22.9
Standard 3: Examining and testing to
support the clinical diagnosis
0 0
Standard 4: Treating and managing the
disease
1 0.6
GPS meeting consensus statement standards for allergic rhinitis.
FIGURE 4-2. Results of a cross-sectional population-based,
epidemiological survey using computer-assisted telephone
interviews to ascertain the prevalence and diagnosis of aller-
gic rhinitis in almost 10,000 adults in 6 European countries.6
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FIGURE 4-3. Number of GPs correctly meeting specific
criteria in the Consensus Statement standards for allergic
rhinitis in a UK survey (n  188).7
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more important. In the UK, for example, the prescription
costs for medicines to treat allergic rhinitis are approximately
£70 million and a further £60–70 million are spent on
over-the-counter (OTC) treatments for allergy. Whether these
OTC products are the most appropriate for the patient is not
known, and there is the possibility that for many patients they
are not receiving optimal therapy. For example, many are
purchasing first-generation antihistamines that may do more
harm than good.9,10
ALLERGIC DISEASES: THE FUTURE
In the UK a working party for the Royal College of
Physicians produced a report. “Allergy the unmet need: a
blueprint for better patient care” . . . that investigated current
practices regarding the disease and made recommendations
for future progress.2 The report looked at disease prevalence
trends, the level of disease burden, diagnostic procedures and
management, and it also provided recommendations regard-
ing training and delivery of services. The working party made
a number of comments relating to the current status of
allergic rhinitis:
Royal College of Physicians Report: Allergy the Unmet
Need2
Y One-third of the population has had a diagnosis of some
sort of allergy
Y In any year, 20% of population will receive treatment for
an allergic disorder
Y Six percent of all GP consultations will be allergy related
and GP-related issues:
Royal College of Physicians Report: GPs and Allergy2
Y GPs are poorly trained in allergy
Y Have little specialist knowledge
Y Very little time with patients
Y Limited access to skin prick testing,
Y Limited access to IgE testing
and they concluded . . . “a cycle of lack of knowledge about
the most common allergic diseases, lack of recognition of
allergic disease at the clinical level, and inadequate knowl-
edge and skills in the diagnosis and treatment of allergic
diseases will be perpetuated.”
The World Allergy Organization has also recognized
the shortcomings of the current situation and they published
a report “Recommendations for Competency in Allergy
Training for Undergraduates Qualifying as Medical Practitio-
ners: A Position Paper of the World Allergy Organization.”11
In the UK, the Government has tried to address this
issue and in 2003/2004 a white paper from the House of
Commons Health Committee. . . “The Provision of Allergy
Services” . . . was published and it recognized the need to
invest in allergy services and concluded by observing that the
current provision of allergy services was manifestly inequi-
table.12 Recommendations included:
Y More recognition at undergraduate level
Y Better training in allergy for GPs
Y Development of GPs with specialist interest (GPSI) in
allergy positions
Y Minimum of 1 allergy center in each of former NHS
regions (5–7 m population)
Y Specialist allergy consultant posts in large teaching
hospitals
ROLE OF GPSI IN ALLERGY
Provision of an efficient allergy service in primary care
will require investment as was recognized by the House of
Commons Health Committee.12 To function effectively it will
highly dependent upon having GPSIs in allergy whose role it
will be to act as champions and mentors in primary care and
to manage more challenging problems in the community; the
overall goal will be to improve services, help educate patients
and colleagues, and to increase awareness (Box 4-1).13
The role will be above and beyond that of providing a
simple clinical service. Fig. 4-4 provides an outline of a
successful GPSI clinic in allergy that was set-up successfully
in London.14 For the GPSI in allergy scheme to be successful
it will require support:
Y From specialist experts in secondary care
Y Access to journals/information (especially “how to do
articles”; often the costs for information are prohibitive)
Y Access to tests
Role of GPs With a Special Interest in Allergy13
1. To manage more challenging problems
• Nasal symptoms unresponsive to combination therapy
• Skin symptoms
• Food allergy and atypical symptoms to food
• Drug reactions
• Generalized insect venom reactions
• Asthma when an allergic trigger is suspected anaphylaxis
2. Advice
• Primary care practitioners
• Primary care organizations and public bodies
3. Access
• Allergy testing (skin prick/IgE testing)
• Imaging





• Public health leads
• Clinical governance
BOX 4-1. Role of GPs with a special interest in allergy.13
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CONCLUSIONS
Y Clear evidence that the prevalence of allergic diseases is
increasing
Y Global shortage of specialist allergists
Y Generally there is a poor understanding of allergy man-
agement in primary care
Y Better education regarding allergy is essential for under-
and postgraduates
Y There is a recognized need that we must deliver care
differently to improve patient outcomes
Y Campaigning for resources, nationally and internation-
ally is essential
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